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PKCθ is essential for the activation of CD4+ T cells. Upon TCR/CD28 stimulation, PKCθ 
is phosphorylated and migrates to the immunological synapse, inducing the activation of 
cellular transcription factors such as NF-κB and kinases as ERK that are critical for HIV-1 
replication. We previously demonstrated that PKCθ is also necessary for HIV-1 replica-
tion but the precise mechanism is unknown. Efficient HIV-1 transcription and elongation 
are absolutely dependent on the synergy between NF-κB and the viral regulator Tat. Tat 
exerts its function by binding a RNA stem-loop structure proximal to the viral mRNA cap 
site termed TAR. Besides, due to its effect on cellular metabolic pathways, Tat causes 
profound changes in infected CD4+ T cells such as the activation of NF-κB and ERK. 
We hypothesized that the aberrant upregulation of Tat-mediated activation of NF-κB 
and ERK occurred through PKCθ signaling. In fact, Jurkat TetOff cells with stable and 
doxycycline-repressible expression of Tat (Jurkat-Tat) expressed high levels of mRNA 
for PKCθ. In these cells, PKCθ located at the plasma membrane was phosphorylated at 
T538 residue in undivided cells, in the absence of stimulation. Treatment with doxycycline 
inhibited PKCθ phosphorylation in Jurkat-Tat, suggesting that Tat expression was directly 
related to the activation of PKCθ. Both NF-κB and Ras/Raf/MEK/ERK signaling pathway 
were significantly activated in Jurkat-Tat cells, and this correlated with high transactiva-
tion of HIV-1 LTR promoter. RNA interference for PKCθ inhibited NF-κB and ERK activity, 
as well as LTR-mediated transactivation even in the presence of Tat. In addition to Tat-
mediated activation of PKCθ in the cytosol, we demonstrated by sequential ChIP that Tat 
and PKCθ coexisted in the same complex bound at the HIV-1 LTR promoter, specifically 
at the region containing TAR loop. In conclusion, PKCθ-Tat interaction seemed to be 
essential for HIV-1 replication in CD4+ T cells and could be used as a therapeutic target.
Keywords: hiV-1 Tat regulator, protein kinase c theta, ras/raf/MeK/erk pathway, nF-kappa B, nuclear 
colocalization, cD4+ T cell activation, PKc theta mrna interference, PKc theta and hiV-1 Tat interaction
inTrODUcTiOn
The human immunodeficiency virus type 1 (HIV-1) infection is characterized by a continuous viral 
replication in CD4+ T lymphocytes and macrophages (1), ultimately leading to the development of 
the acquired immunodeficiency syndrome (AIDS). The preferential targets of HIV-1 are the activated 
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CD4+ T cells from the gut-associated lymphoid tissue (GALT) 
(2, 3), where the virus performs a massive replication during the 
early stages of the illness. During this massive activation, two 
major events occur. First, viral reservoirs with the provirus inte-
grated in the host-cell DNA are generated and persist in latency, 
representing an insuperable obstacle for the eradication of the 
infection (4–6). Second, the major target of HIV-1, CD4+ T cells, 
is progressively depleted, which eventually leads to AIDS (7, 8). 
Although HIV-1 may infect both resting and activated CD4+ T 
cells, it can only replicate in activated cells (9). Therefore, CD4+ T 
cell activation is essential to sustain HIV-1 replication.
The novel protein serine/threonine kinase C (PKC) theta 
(θ) isoform is selectively expressed in T lymphocytes (10) and 
is essential for TCR/CD3-mediated T-cell activation (11, 12). 
PKCθ kinase activity is regulated by phosphorylation of different 
residues during T-cell activation (13, 14). Phosphorylation of T538 
on the catalytic domain has been described as critical for PKCθ 
kinase activity and for inducing NF-κB activation (15). Therefore, 
the phosphorylation of this residue is often used as surrogate 
marker of PKCθ activation (14) and can be detected in dividing 
cells. Once phosphorylated at T538, PKCθ is translocated to the 
plasma membrane lipid rafts during the immunological synapse 
(16), inducing the activation of signaling pathways such as Ras/
Raf/MEK/ERK and transcription factors such as NF-κB (17). 
NF-κB is critical for the regulation of key immune genes as inter-
leukin-2 (IL-2) (12, 18) and for the replication of HIV-1 (19). Our 
group previously described that PKCθ catalytic activity is essen-
tial for HIV-1 replication, as shown by PKCθ mRNA interference 
(20) or the use of selective PKCθ inhibitors (21), which reduced 
HIV-1 replication in CD4+ T cells and induced a refractory state 
to HIV-1 infection. Although the role of PKCθ in the cytoplasm 
and at the immunological synapse has been extensively studied, 
PKCθ was recently described in the nucleus of activated T cells as 
part of an active transcription complex with RNA polymerase II 
(RNAPII) assembled at the IL-2 promoter (22).
The viral transcriptional regulator Tat is critical for HIV-1 gene 
expression and replication (23). Tat binding site within the viral 5′ 
long terminal repeat (LTR) promoter of the integrated provirus 
is a stem-loop RNA termed trans-activation response (TAR) ele-
ment that is located at the 5′-end of all nascent viral transcripts 
(24). TAR is located downstream the viral LTR promoter, a region 
spanning from nucleotide position +1 to +59. Tat/TAR binding 
enables efficient viral transcript elongation through the recruit-
ment of cellular factors from the basal transcriptional machinery 
such as the positive transcription elongation factor b (P-TEFb) to 
increase the processivity of RNAPII (25). P-TEFb is composed of 
cyclin T1, which directly interacts with Tat to permit the binding 
to TAR (26), and the cyclin-dependent kinase 9 (CDK9) that 
hyperphosphorylates RNAPII at the carboxy terminal domain 
(CTD) to ensure efficient elongation of the viral transcripts (27). 
Tat shows a predominant nuclear distribution in infected CD4+ 
T cells although it can also be released into the extracellular 
medium and taken up by adjacent non-infected cells (28). The tat 
coding gene consists of two spliced exons separated by more than 
2,300 nucleotides in the HIV-1 genome. After complete splicing 
of the viral pre-mRNA, a highly conserved protein composed 
of 101 residues is synthesized (Tat101) (29). The first exon of 
Tat (1–72 aa, Tat72) contains the minimal functional domain 
to generate a protein competent in HIV-1 replication (30) but 
Tat101 is the most common protein in clinical HIV-1 isolates 
(31). Our group previously demonstrated that Tat101 was more 
competent than Tat72 in causing deregulation in gene expression 
and cytoskeleton modifications due to the presence of the peptide 
encoded by the second exon, a high-positive charged region of 29 
aa that would enhance the binding strength or affinity to host cell 
targets, providing more activity to Tat101 than Tat72 (32). As part 
of the modifications caused in the CD4+ T cells, Tat induces the 
activation of several transcription factors in CD4+ T cells such as 
NF-κB, NFAT, Sp1, and kinases such as ERK (32–34), although 
the precise mechanisms involved are currently controversial.
In this study, we analyzed the effect of two essential factors, 
cellular PKCθ and viral Tat, on HIV-1 replication and their pos-
sible interaction in the nucleus of CD4+ T cells. PKCθ-mediated 
pathways such as Ras/Raf/MEK/ERK and NF-κB were analyzed 
in Jurkat cells with stable expression of Tat101 and Tat72 proteins. 
Even in the absence of stimulation, Jurkat-Tat101 cells showed 
increased PKCθ expression levels as well as T538 phosphorylation, 
which correlated with increased Ras/Raf/MEK/ERK and NF-κB 
activity. Analysis of nuclear colocalization and chromatin interac-
tion provided support for the coexistence of PKCθ and Tat within 
the nucleus, and that they were interacting at the LTR promoter, 
specifically within the region of TAR loop.
MaTerials anD MeThODs
cells
Jurkat E6-1 cells were obtained from the NIH AIDS Reagent 
Program (35). By using a TetOff system (BD Biosciences Clontech, 
Mountain View, CA, USA), Jurkat-Tat72 and Jurkat-Tat101 stably 
express the first exon of HIV-1 Tat (1–72 aa) or the full-length Tat 
(1–101 aa), respectively. Jurkat TetOff cells transfected with empty 
vector pTRE2hyg were used as negative control. Jurkat-Tat72 
and Jurkat-Tat101 are not clones but mixed populations in which 
more than 50% of the cells express high amounts of intracellular 
Tat101 or Tat72 protein. The expression of Tat in Jurkat-Tat101 
and Jurkat-Tat72 mimicked the real infection performed in MT-2 
cells infected with the NL4.3wt strain (32). Jurkat E6-1 cells were 
cultured in RPMI 1640 medium supplemented with 10% (v/v) 
fetal calf serum (FCS), 2  mM l-glutamine, 100 μg/ml strepto-
mycin, and 100 U/ml penicillin (Biowhittaker, Walkersville, MD, 
USA). In Jurkat-Tat cells, the culture medium was supplemented 
with 300  μg/ml of geneticin (Sigma-Aldrich, St. Louis, MO, 
USA) and 300 mg/ml hygromycin B (BD Biosciences Clontech). 
Tat expression was controlled by adding 1  μg/ml doxycycline 
(BD Biosciences Clontech) to the culture medium for 3  days. 
Peripheral blood lymphocytes (PBLs) were isolated from blood 
of healthy donors by centrifugation through a Ficoll–Hypaque 
gradient (Lymphocyte Separation Medium, Lonza). Cells were 
collected in supplemented RPMI 1640 medium and maintained 
at 37°C, 2 × 106 cells/ml. Phytohemagglutinin (PHA)-treated T 
lymphocytes were obtained from PBLs cultured for 3 days in the 
presence of 5 μg/ml PHA (Sigma-Aldrich, St. Louis, MO, USA) 
and 300 U/ml IL-2 (Chiron, Emeryville, CA, USA).
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Vectors
Plasmid pCMV-tat101 was previously described (36). Long 
terminal repeat (LTR) vector containing the luciferase (LUC) 
reporter gene under the control of HIV-1 LTR U3 +  R region 
(LAI strain) (pLTR-LUC) was described previously (37). To 
detect Elk-1 activity, Jurkat cells were cotransfected with 16 ng 
pCDNAIII-Gal4-Elk1, 0.1  μg pRL-TK (containing the Renilla 
LUC gene under control of the HSV-TK promoter), and 0.3 μg 
pGal4-LUC (containing luc gene controlled by six copies of Gal4 
responsive element) per million of cells, as previously described 
(38). Vector pNL4-3 wild-type (wt) kindly provided by Dr. M. A. 
Martin (39) contained the HIV-1 complete genome and induced 
an infectious progeny after transfection. pNL4-3_TatM1I, which 
contains a point mutation in the start codon of the tat gene, 
was obtained from pNL4-3_wt by site-directed mutagenesis as 
previously described (40). pNL4-3_TatM1I was cotransfected 
along with pCMV-Tat101 in a 2:1 proportion. GeneClip U1 
Hairpin Cloning System kit (Promega Biotech Iberica, Madrid, 
Spain) was used to generate the small hairpin RNA (shRNA) 
plasmids pGeneClip-iPKCθ-1 and pGeneClip-iPKCθ-3 contain-
ing two different small interference RNA (siRNA) sequences 
directed against mRNA encoding for PKCθ, and the control 
vector pGeneClip-iPKCθ-C1 with scrambled sequences, as was 
described in Ref. (40). All plasmids were purified using Qiagen 
Plasmid Maxi Kit (Qiagen Iberia, Madrid, Spain), following the 
manufacturer’s instructions.
antibodies and reactives
Monoclonal antibody against HIV-1 Tat (aa 2–9) was obtained 
from Advanced Biotechnologies Inc. (Columbia, MD, USA). 
Specific antibody against p65/RelA (clone C-20) was supplied 
by Santa Cruz Biotechnology (Santa Cruz, CA, USA). Specific 
antibody against the β-isoform of actin was obtained from Sigma 
Aldrich. Polyclonal antibodies against human PKCθ and PKCδ 
were purchased from Santa Cruz Biotechnology. Polyclonal 
antibodies against phospho-PKCθ (Thr538), phospho-PKCδ 
(Thr505), total c-Raf/Raf-1, phospho-c-Raf/Raf-1 (Ser338), total 
MEK1/2, phospho-MEK1/2 (Ser217/221), total p44/42 MAPK 
(Erk1/2), and phospho-Erk1/2 (Thr202/Tyr204) were obtained 
from Cell Signaling Technology (Danvers, MA, USA). Secondary 
antibodies conjugated with horseradish peroxidase (HRP) were 
purchased from GE Healthcare (Uppsala, Sweden). Secondary 
antibodies conjugated to Alexa 488, Alexa 555, and Alexa 633 
were purchased from Molecular Probes (Eugene, OR, USA). 
5-phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich) was 
used at 25 ng/ml.
Quantitative Pcr assay
Total RNA was isolated with RNeasy Mini kit (Qiagen Iberia), and 
cDNA was synthesized by using the GoScript Reverse Transcription 
System (Promega), according to manufacturers’ instructions. 
HIV-1 transcription was determined by quantitative PCR (qPCR) 
analysis of all viral mRNAs using the following primers to amplify 
PRKCQ gene: PKCt7_s (5′-GCAATTTCGACAAAGAATT-3′) 
and PKCt5_as (5′-ATTGTTGAGTGTTTCTTTC-3′); and 
PRKCD gene: PKCd3_s (5′-GCTGCCATCCACAAGAAAT-3′) 
and PKCd4_as (5′-ACTTTAATCCCTGCTTCAC-3′). The 
expression of β-actin was used as housekeeping gene to 
calculate the relative expression of PRKCQ and PRKCD. 
Primers for amplifying human β-actin gene were β-actin-s 
(5′-AGGCCCAGAGCAAGAGAGGCA-3′) and β-actin-as 
(5′-CGCAGCTCATTGTAGAAGGTGTGGT-3′). qPCR was 
performed in a StepOnePlus Real-Time PCR System, using 
StepOne v3.2 software (Life Technologies, Carlsbad, CA, USA). 
SYBR Green PCR Master Mix (Applied Biosystems) was used 
according to manufacturer’s instructions.
PKc Kinase assays
PKCθ and PKCδ enzymatic activity was assayed in Jurkat-
Tat cells using an immunoprecipitation kinase assay as 
described previously (41), with minor modifications as 
described in Ref. (20). Protein extracts (250–500  μg) were 
immunoprecipitated for 18 h at 4°C using 2 μg of anti-PKCθ 
or anti-PKCδ antibodies. The immunoprecipitates were incu-
bated with goat anti-rabbit IgG (whole molecule) antibody 
conjugated with agarose (Sigma-Aldrich). The enzymatic 
reaction was performed by using PKCϵ peptide substrate 
ERMRPRKRQGSVRRRV (Merck Millipore, Darmstadt, 
Germany). As a negative control, one reaction with the goat 
anti-rabbit IgG antibody conjugated with agarose (Sigma-
Aldrich) was performed without adding the primary anti-
body to the cytosolic extracts. A complete reaction mixture 
lacking of PKCϵ peptide substrate was used as blank solution. 
Radioactivity was counted in a Beckman LS 6000L scintil-
lation counter (Beckman Instruments, Fullerton, CA, USA). 
The corrected cpm (counts per minute) was determined by 
subtracting the blank control value.
Transient Transfection
Jurkat cells were transiently transfected with an Easyjet Plus 
Electroporator (Equibio, Middlesex, UK). In brief, 20 × 106 PBLs 
or 107 Jurkat were collected in 350 μl of RPMI without supplement 
and mixed with 1 μg/106 cells of each plasmid DNA. Cells were 
transfected in a cuvette with 4-mm electrode gap (EquiBio) at 280 V, 
1500 μF, and maximum resistance. After transfection, cells were 
incubated in supplemental RPMI at 37°C for 18 h. LUC activity 
was assayed using Luciferase Assay System (Promega), according to 
manufacturer’s instructions. Relative light units (RLUs) were meas-
ured with a Sirius luminometer (Berthold Detection Systems, Oak 
Ridge, TN, USA) after the addition of the appropriate substrate. 
RLUs were normalized by measuring total protein concentration 
with the method of Bradford (42). pEYFP-C1 vector (BD Biosciences 
Clontech) was cotransfected as control of transfection efficiency and 
measured by flow cytometry using a FACScalibur Flow Cytometer 
and CellQuest software (BD Biosciences). Interference of mRNA 
for PKCθ was performed by transient transfection of Jurkat cells 
with pGeneClip-iPKCθ-1 and pGeneClip-iPKCθ-3 vectors (1:1), 
using pGeneClip-iPKCθ-C1 as control.
hiV-1 infection
Briefly, 10 × 106 of Jurkat E6-1 cells were incubated 2 h at gently 
rotation and room temperature with 0.5  μg/ml of p24-gag of 
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NL4-3 infectious supernatant obtained from calcium phosphate 
transfection of 293T cells with plasmid pNL4-3_wt. Cells were 
then centrifuged at 2,500 rpm for 30 min at 25°C, and washed 
five times with 1× PBS. After incubation for 7 days, cells were 
analyzed by immunofluorescence. Quantification of p24 was 
performed by Innotest HIV Antigen mAb assay (Innogenetics 
Diagnostica Iberia, Barcelona, Spain).
immunofluorescence assays
For immunofluorescence assays, cells were immobilized in 
PolyPrep slides (Sigma-Aldrich) for 15 min and then fixed with 
2% paraformaldehyde (PFA)–0.025% glutaraldehyde in 1× PBS 
for 10 min at room temperature. After washing twice with 0.1% 
glycine/PBS, cells were permeabilized with 0.1% Triton X-100/
PBS. Incubation with each primary and secondary antibodies and 
subsequent washes were performed with 1× PBS–2% BSA–0.05% 
saponine buffer. 4′,6-diamidino-2-phenylindole (Dapi) was 
used for nuclear staining while cholera toxin B subunit FITC 
(fluorescein isothiocyanate) conjugate was used as marker of 
membrane lipid rafts (Sigma-Aldrich). Images were obtained 
with Leica TCS-SP confocal microscope or Leica DMI 4000B 
Inverted Microscope (Leica Microsystems, Wetzlar, Germany). 
The intensity mean per pixel was calculated in confocal images 
using LAS AF Lite software (Leica Microsystems), and values 
were represented in bar diagrams showing statistical significance.
Flow cytometry
Intracellular staining was performed after fixing the cells with 1% 
PFA in 1× PBS for 1 h. Incubation with primary and secondary 
antibodies was performed with 1× PBS-0.5% Tween-20. Cells 
were analyzed on a FACScalibur Flow Cytometer using CellQuest 
software (BD Biosciences).
immunoblotting assays
Cytosolic, nuclear, and membrane protein fractions were obtained 
as described previously (43, 44) and protein concentration was 
determined by Bradford method (42). Proteins were fractionated 
by sodium dodecyl sulfate-polyacrilamide gel electrophoresis 
(SDS-PAGE) and transferred onto Hybond-ECL nitrocellulose 
paper (GE Healthcare-Madrid, España). After blocking and 
incubation with primary and secondary antibodies, proteins 
were detected with SuperSignal West Pico Chemiluminescent 
Substrate (Pierce, Rockford, IL, USA). Images were acquired in 
a BioRad Geldoc 2000 (BioRad, Hercules, CA, USA), and den-
sitometry analysis was performed using Quantity One software 
(BioRad). Relative ratio of optical density units was calculated 
regarding to the gel band corresponding to the internal control 
for each lane and each type of protein extracts after subtracting 
the background noise.
Dna affinity immunoblotting assay
DNA affinity immunoblotting (DAI) assay was performed as 
previously described in Ref. (45) with minor modifications. 
Briefly, 100 μg of nuclear protein extracts from each cell line were 
incubated at 4°C for 30 min with 25 nM of a 5′ end-labeled biotin 
probe that contains the double-κB consensus motif located in the 
HIV-1 LTR promoter (5′-AGCTTACAAGGGACTTTCCGCTG 
GGGACTTTCCAGGGA-3′), with this probe mutated at the -κB 
consensus sites (5′-AGCTTACAACTCACTTTCCGCTGCTC 
ACTTTCCAGGGA) or with a probe that contains the estrogen 
receptor (ER) DNA element, a non-related NF-κB gene (46). 
Biotin-probe/protein complexes were captured by incubating 
with streptavidin agarose resins (Pierce) at 4°C for 30 min and 
then collected by centrifugation. Protein complexes were fraction-
ated by SDS-PAGE, and the presence of p65/RelA protein bound 
to DNA probes was detected by immunoblotting with a specific 
antibody (clone C-20; Santa Cruz Biotechnology). As internal 
control 10 μg of protein were separated before adding each probe 
and resolved by Western-blot using an antibody against β-actin 
(Sigma-Aldrich). Images were acquired in a BioRad Geldoc 
2000 (BioRad), and densitometry analysis was performed using 
Quantity One software (BioRad) as described above.
assay for Detection of activated ras
Detection assay for activated Ras were performed as previously 
described (47) with modifications. Briefly, Jurkat-Tat cells were 
subjected to serum deprivation for 2 h and then lysed with lysis 
buffer (25 mM pH 7.5 HEPES, 1% Triton X-100, 150 mM NaCl, 
10 mM MgCl2, and protease inhibitors). For affinity precipitation, 
lysates were incubated with purified GST-Raf-RBD protein pre-
bound to glutation-Sepharose (GE Healthcare). Bound proteins 
were eluted and analyzed by immunoblotting using a specific 
antibody against N-Ras (SantaCruz Biotechnology). β-actin was 
used as internal loading control.
sequential immunoprecipitation of 
chromatin
Sequential immunoprecipitation of chromatin (ChIP) assays 
were performed on Jurkat E6-1 cells transfected with pNL4-3_wt 
according to the protocol supplied by Upstate Biotechnology, as 
previously detailed (22). Antibodies used were directed against 
PKCθ (clone C-18, SantaCruz Biotechnology) and HIV-1 Tat 
(clone 02-010, SantaCruz Biotechnology). qPCR with primers 
spanning across the region from −39 to +66 on the HIV-1 LTR 
promoter assessed the recovery of immunoprecipitated DNA, 
calculated as relative ChIP enrichment. The primers used were: 
sense 5′-TCAGATGCTACATATAAGCAGCTGCT-3′ and anti-
sense 5′-AAGCAGTGGGTTCCCTAGTTAGCC-3′. ChIP-PCR 
data were collated from two independently repeated experiments 
(N = 2).
statistical analysis
Statistical analysis was performed using GraphPad Prism software 
(GraphPad, La Jolla, CA, USA). Comparisons between groups 
were made using two-way analysis of variance (ANOVA) with 
Bonferroni posttest analysis to describe the statistical differences 
among groups. For comparison between less than three groups 
one-tailed Mann–Whitney test was used. The P values (p) < 0.05 
were considered statistically significant in all comparisons and 
were represented as *, **, ***, or **** for p <  0.05, p <  0.01, 
p < 0.001, or p < 0.0001, respectively.
FigUre 1 | infection of Jurkat cells with hiV-1 induced PKcθ phosphorylation at T538. Phosphorylation of PKCθ at T538 in Jurkat E6-1 infected with the 
infectious clone NL4-3_wt for 7 days (a) were analyzed by confocal microscopy and compared with uninfected cells (B). Progression of the infection was 
determined by quantification of HIV-1 p24 (ng/ml) 7 days postinfection (c).
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resUlTs
infection of Jurkat cells with hiV-1 
induced PKcθ Phosphorylation at T538
Jurkat E6-1 cells infected with HIV-1 clone NL4-3_wt for 7 days 
were stained with an antibody against PKCθ phosphorylated 
at T538 and analyzed by confocal microscopy. Levels of PKCθ 
phosphorylated at T538 increased in infected cells (Figure  1A) 
compared to uninfected control cells (Figure 1B). Selection of the 
optical section through the middle of the cell – z axis – showed 
that phospho-PKCθ had an intracellular distribution, and it was 
also located inside the nucleus. Progression of the infection was 
monitored by quantification of p24 by ELISA after 7 days of infec-
tion (Figure 1C).
PKcθ mrna and Kinase activity are 
enhanced in Jurkat cells with stable 
expression of hiV-1 Tat
Expression of mRNA and protein for PKCθ and the structur-
ally related PKCδ was analyzed by quantitative PCR (qPCR) 
and immunoblotting, respectively, in Jurkat cells with stable 
intracellular expression of Tat101 (codified by first and second 
exons) and Tat72 (codified by first exon). PKCθ expression level 
was increased in both Jurkat-Tat72 (p < 0.05) and Jurkat-Tat101 
(p < 0.01) compared to control cells, whereas the expression of 
mRNA and protein for PKCδ was slightly reduced (Figure 2A). 
PKCθ and PKCδ kinase activities were analyzed to evaluate if 
the increase in mRNA was related to an increased kinase activ-
ity. PKCθ kinase activity was enhanced in Jurkat-Tat101 cells 
(p < 0.001) relative to control cells, and this increase was lower in 
Jurkat-Tat72 (Figure 2B). No significant change in PKCδ kinase 
activity was detected in Jurkat-Tat cells.
Phosphorylation of PKcθ at T538 Was 
increased in Jurkat-Tat cells
Intracellular expression of phosphorylared PKCθ at T538 was 
analyzed by flow cytometry in Jurkat-Tat cells after staining with 
a specific antibody. Jurkat-Tat101 cells showed increased PKCθ 
phosphorylation (17.91% more than in control cells) in the 
absence of activation (Figure 3A, right histogram). There were 
no significant changes in Jurkat-Tat72 cells, in relation to control 
cells (Figure 3A, left histogram). Translocation of PKCθ phos-
phorylated at T538 was analyzed by immunofluorescence using a 
specific antibody. Lipids rafts were stained with FITC to identify 
the plasma membrane, and nuclei were stained with Dapi. In 
comparison to Jurkat-Tat72 and control cells, in non-dividing 
FigUre 2 | PKcθ mrna expression and kinase activity were 
enhanced in Jurkat-Tat101 cells. Expression of mRNA and protein for 
PKCθ and PKCδ, analyzed by qPCR and immunoblotting, respectively, (a), 
as well as kinase activity for PKCθ and PKCδ (B), were quantified in 
Jurkat-Tat101 and Jurkat-Tat72, regarding control cells. Data are represented 
as mean ± SEM. *, **, or *** for p < 0.05, p < 0.01, or p < 0.001, 
respectively.
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Jurkat-Tat101 cells, there was an increased localization of PKCθ 
phosphorylated at T538 on the plasma membrane (Figure 3B, left 
panel). Furthermore, treatment with PMA for 15 min induced 
translocation of phospho-PKCθ to the plasma membrane in divid-
ing cells across all cell types (Figure 3B, right panel). This result 
was also analyzed by immunoblotting and relative quantification 
was performed by densitometry. In control cells, phospho-PKCθ 
at the cytosol was translocated to the plasma membrane within 
15  min of PMA treatment (Figure  3C). In Jurkat-Tat72 cells, 
phospho-PKCθ was already detected at the plasma membrane 
in basal conditions, but it was increased after treatment with 
PMA. Interestingly, high quantity of phospho-PKCθ was already 
detected at the plasma membrane of Jurkat-Tat101 cells under 
basal conditions, a level that was comparable to the PMA treat-
ment with no significant changes. Phosphorylation of PKCδ did 
not significantly change in both Jurkat-Tat cells in basal condi-
tions but increased in the plasma membrane after treatment with 
PMA. Expression of p65/RelA and p56Lck was used, respectively, 
to discard the possible contamination of plasma membrane pro-
teins with cytosolic proteins or cytosolic proteins with plasma 
membrane proteins. β-actin was used as loading control.
The importance of increased PKCθ phosphorylation at T538 
on Tat101 expression in Jurkat-Tat101 cells was further analyzed 
after treating these cells with doxycycline for 3 days to eliminate 
Tat101 expression using the TetOff system. Treatment with 
doxycycline completely impeded PKCθ phosphorylation at T538 
in both Jurkat-Tat101 and Jurkat-Tat72 cells after transfection 
with pNL4-3_TatM1I clone, which remains non-infectious unless 
Tat is externally provided, as was determined by immunoblotting 
(Figure  3D). Progression of the infection was determined by 
quantification of HIV-1 p24 (ng/ml).
increased nF-κB activity in Jurkat-Tat 
cells Was reduced by the interference of 
mrna for PKcθ
One of the final effectors of PKCθ signaling pathway is NF-κB, 
a cellular transcription factor that is essential for T-cell survival 
(48) and HIV-1 replication (19). Regardless of PMA treatment, 
DAI demonstrated that there was an increased binding of p65/
RelA – the most important component of NF-κB in T lympho-
cytes –  to the κB promoter in Jurkat-Tat101 cells (Figure 4A). 
This increased NF-κB binding was inhibited in Jurkat-Tat101 
cells by cotransfection of siRNA against PKCθ (Figure 4B), prov-
ing that increase in NF-κB activity was dependent on enhanced 
activation of PKCθ in Jurkat-Tat101 cells. Moreover, cotransfec-
tion of a Luciferase expression vector under the control of the 
LTR promoter (pLTR-LUC) and siRNA against PKCθ greatly 
reduced the production of LUC in Jurkat-Tat cells (Figure 4C). 
Transient transfection of shRNA plasmids pGeneClip-iPKCθ-1 
and pGeneClip-iPKCθ-3 directed against mRNA encoding for 
PKCθ produced between 40 and 75% of stable RNA interference 
in Jurkat cells, as was previously described (20).
ras/raf/MeK/erK Pathway Was 
increased in Jurkat-Tat cells and Was 
inhibited by rna interference for PKcθ
Ras/Raf/MEK/ERK signal transduction pathway and the 
activation of the downstream transcription factor Elk-1 
(Figure 5A) were analyzed in Jurkat-Tat cells to evaluate the 
role of PKCθ in activating this signaling pathway. First, Ras 
activity was analyzed in Jurkat-Tat cells by using Ras-GTP 
assay and it was increased in Jurkat-Tat cells regarding control 
cells (Figure 5B). Raf/MEK/Erk pathway was also analyzed by 
immunoblotting in Jurkat-Tat cells using specific antibodies 
against phosphorylation sites involved in the activation of c-Raf 
(S338), MEK1/2 (S217/221), and ERK1/2 (T202/Y204) (Figure  5C). 
All these sites were phosphorylated in Jurkat-Tat101 cells in 
basal conditions and phosphorylation further increased upon 
PMA treatment, mostly in ERK1/2 at T202/Y204 (Figure  5D). 
As a consequence, Elk-1 activity was also increased in Jurkat-
Tat101 cells in basal conditions and after treatment with PMA 
for 4 h (Figure 5E). The role of PKCθ in this signaling pathway 
was determined by transfection of siRNA against mRNA for 
FigUre 3 | Phosphorylation of PKcθ at T538 and translocation to the plasma membrane were increased in Jurkat-Tat101 cells. Phosphorylation level of 
PKCθ at T538 was quantified in Jurkat-Tat cells by flow cytometry after intracellular staining, which was compared to the negative control and basal control (Jurkat 
TetOff) (a). Phosphorylation of PKCθ at T538 and translocation to the plasma membrane were analyzed in Jurkat-Tat cells by fluorescence microscopy (B) and 
immunoblotting in basal conditions and after treatment with PMA for 15 min (c, cytosol; m, plasma membrane). Expression of p65 was used to detect contamination 
of plasma membrane proteins with cytosolic proteins and p56Lck to detect contamination of cytosolic with plasma membrane proteins. Densitometry was performed 
to quantify the relative expression of phospho-PKCθ (c). Levels of phospho-PKCθ were analyzed by immunoblotting in protein extracts from the plasma membrane 
of Jurkat-Tat cells transfected with pNL4-3_TatM1I and treated with doxycycline for 3 days. Progression of the infection was monitored by quantification of HIV-1 
p24 (ng/ml) (D).
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PKCθ in Jurkat-Tat cells and subsequent analysis of ERK1/2 
phosphorylation at T202/Y204 (Figure  5F). RNA interference 
for PKCθ caused more than seven times reduction in ERK1/2 
phosphorylation in Jurkat-Tat101 cells, compared to cells 
without interference.
PKcθ coexisted with Tat at the hiV-1 lTr 
Promoter in Jurkat cells
Phosphorylation of PKCθ at T538 and its translocation to the 
plasma membrane is usually used as a surrogate marker of PKCθ 
activation (4–6, 14). However, we also detected this phosphoryl-
ated form of PKCθ in the nucleus by immunofluorescence of 
HIV-infected Jurkat cells (Figure 6A). Because increased PKCθ 
activity appeared to be dependent on the intracellular expression 
of Tat in Jurkat-Tat101 cells, we analyzed whether phospho-PKCθ 
was colocalizing with Tat in the nucleus. In order to synthe-
size large quantity of Tat, Jurkat E6-1 cells were transiently 
transfected with Tat101 expression vector (pCMV-Tat101) and 
incubated for 48  h. Analysis by immunofluorescence micros-
copy proved that those cells with higher expression of Tat101 
FigUre 4 | increased nF-κB activity in Jurkat-Tat cells was dependent on PKcθ activation. Binding of p65/RelA to κB consensus sites in Jurkat-Tat cells 
treated or not with PMA was analyzed by DAI assay (a). The same experiment was performed in Jurkat-Tat cells transfected with siRNA directed against mRNA for 
PKCθ. Analysis by immunoblotting of the level of PKCθ interference is shown (B). Densitometry analysis was done to calculate relative p65/RelA expression and 
showed as horizontal bar diagrams (a,B). Interference of mRNA for PKCθ in Jurkat-Tat cells transfected with a luciferase expression vector under the control of LTR 
promoter (pLTR-LUC) was analyzed by chemiluminescence. Data are represented as mean ± SEM. *** for p < 0.001 (c).
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showed also higher phosphorylation of PKCθ at T538 with a 
preferential nuclear distribution (Figure 6A). Analysis of these 
cells by confocal microscopy of an optical section through the 
middle of the cell – z axis – determined the nuclear localiza-
tion of both Tat and PKCθ (Figure 6B). The intensity mean per 
pixel was calculated in colocalization spots using LAS AF Lite 
software (Leica Microsystems), and values were represented in 
bar diagrams showing statistical significance (Figure 6C). The 
presence of PKCθ in the nucleus was also analyzed by immuno-
blotting in Jurkat-Tat101 cells. PKCθ showed nuclear localiza-
tion in Jurkat-Tat101 and part of it was phosphorylated at T538, 
in comparison with control cells (Figure 6D). This correlated 
with a higher nuclear localization of p65/RelA. Expression of 
p105/NFκB1 and the histone H1 was used to discard the pos-
sible contamination of nuclear proteins with cytosolic proteins 
or cytosolic proteins with nuclear proteins, respectively. β-actin 
was used as loading control and as control for the densitometry 
analysis.
To evaluate whether Tat and PKCθ were directly interacting 
at the HIV-1 LTR promoter, sequential immunoprecipitation of 
chromatin (ChIP) was performed with DNA obtained from Jurkat 
E6-1 cells transfected with HIV-1 pNL4-3_wt infectious clone 
and from human PBLs infected with NL4-3_wt strain for 3 days. 
A primary ChIP was carried out using an antibody against Tat 
followed by a secondary ChIP using an antibody against PKCθ. 
qPCR analysis was performed on immunoprecipitated DNA using 
primers directed against specific regions of HIV-1 LTR promoter. 
Sequential ChIP analysis revealed that Tat and PKCθ coexisted on 
the HIV gene promoter in both Jurkat and PBLs (Figure 7), and 
that PKCθ was enriched at the region located within −39 and +66 
that includes TAR loop. These sites could be the preferred binding 
sites for PKCθ at the HIV promoter.
DiscUssiOn
hiV-1 infection increased Phosphorylation 
of PKcθ at T538
HIV-1 primary infection is characterized by a massive activation 
of CD4+ T cells responsible for its depletion and for the generation 
of the viral reservoirs that impede the eradication of the infection 
(4–6). HIV-1 can infect resting and activated CD4+ T cells but full 
replication can only occur in activated cells (9). Therefore, control 
FigUre 5 | increased activation of ras/raf/MeK/erK/elk-1 pathway in Jurkat-Tat cells was dependent on PKcθ activation. Schematic representation 
of the Ras/Raf/MEK/ERK/Elk-1 pathway (EGFR, epidermal growth factor receptor) (a). Analysis by immunoblotting of Ras-GTP activity in Jurkat-Tat cells (B). 
Analysis by immunoblotting of phosphorylated and total proteins of the Ras/Raf/MEK/ERK pathway in Jurkat-Tat cells in basal conditions (c) and after activation 
with PMA for 15 min (D). Analysis by chemiluminescence of Elk1 activity in Jurkat-Tat cells in basal conditions and after treatment with PMA. Data are represented 
as mean ± SEM. *** for p < 0.001 (e). Analysis by immunoblotting of levels of ERK1/2 phosphorylation at T202/Y204 after RNA interference of PKCθ in Jurkat-Tat 
cells (F). Densitometry analyses were performed to calculate relative protein expression and showed as horizontal bar diagrams (B–D,F).
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FigUre 6 | nuclear colocalization of PKcθ and Tat in Jurkat cells. Nuclear colocalization of PKCθ and Tat was analyzed in Jurkat E6-1 cells transiently 
transfected with pCMV-Tat101 for 48 h by using fluorescence microscopy (a) and confocal microscopy (B). The intensity mean per pixel was calculated in colocalization 
spots and values were represented in bar diagrams showing statistical significance (c). Data are represented as mean ± SEM. **** for p < 0.0001. Nuclear presence of 
total and phosphorylated (T538) PKCθ was also analyzed by immunoblotting. Expression of p65/RelA was also determined. Analysis of p105/NFκB1 was used to detect 
contamination of nuclear proteins with cytosolic proteins and histone H1 to detect contamination of cytosolic (c) with nuclear (n) proteins. β-actin was used as internal 
loading control. Densitometry analyses were performed to calculate relative protein expression, according to β-actin for each lane, and showed as a bar diagram (D).
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of CD4+ T cell activation during HIV-1 primary infection could 
regulate viral replication, decreasing the size of the reservoir, 
and reducing the depletion of CD4+ T cells. In this regard, our 
group described previously the important role of PKCθ in HIV-1 
replication, as the interference of mRNA for PKCθ (20) or the 
use of selective PKCθ inhibitors (21) hindered HIV-1 replication 
in CD4+ T cells. We also observed that HIV-1 infection induced 
PKCθ activation by increasing its phosphorylation at T538 and 
subsequent translocation to the plasma membrane, events that 
are usually used as surrogate markers of PKCθ kinase activity 
(14). However, the mechanism by which HIV-1 could induce 
PKCθ phosphorylation in the absence of activating stimuli 
remains unknown.
intracellular expression of Tat101 
increased PKcθ activity in Jurkat cells
Activation of PKCθ initiates several transducing pathways in T 
cells such as Ras/Raf/MEK/ERK and NF-κB (17). Both ERK and 
NF-κB have been described as essential for HIV-1 replication 
(19, 49, 50). They act in synergy with viral proteins as Nef (51) 
and the viral regulator Tat (19) to increase HIV-1 transcription. 
Tat is responsible for efficient transcription and elongation of 
the viral transcripts because it binds to TAR loop at the LTR 
promoter and recruits cellular factors such as P-TEFb to increase 
RNAPII hyperphosphorylation of the CTD (27). Fully active Tat 
protein (Tat101) is codified in two separated exons that conform 
a unique mRNA sequence after multiple splicing (52), but the 
protein codified by the first exon (Tat72) retains most of the abil-
ity to induce an efficient viral transcription (30). Both Tat101 and 
Tat72 show a predominant nuclear localization in the infected 
cells, although Tat may also be released to the extracellular 
medium and captured by neighboring cells, causing cytotoxicity 
(53). Although the action of signaling kinases was traditionally 
thought to occur predominantly in the cytoplasm, a new nuclear 
role for PKCθ was recently described as part of an active complex 
with RNAPII, attached to specific promoter regions (22). Based 
on this assertion, we evaluated the possible interaction between 
PKCθ and Tat in the nucleus of CD4+ T cells and their effect on 
HIV-1 replication. The role of Tat on the activation of PKCθ 
signaling pathways as Ras/Raf/MEK/ERK/Elk-1 and NF-κB were 
also analyzed.
Our group developed Jurkat cell lines with stable intracel-
lular expression of Tat101 and Tat72 by using the TetOff system. 
Jurkat-Tat72 and Jurkat-Tat101 cell lines are not clones but 
mixed populations in which more than 50% of the cells express 
high amounts of intracellular Tat101 or Tat72 protein (32). Tat 
intracellular expression could be abrogated in Jurkat-Tat cells 
after incubation with doxycycline for 3  days. It was observed 
that not only the expression of mRNA for PKCθ was increased in 
Jurkat-Tat101 cells but PKCθ kinase activity was also enhanced 
in these cells. In Jurkat-Tat72 cells, expression of mRNA for 
PKCθ was increased, but it did not translated into an increased 
kinase activity, proving that the presence of the second exon in 
Tat101 was crucial for this effect of Tat on the activation of PKCθ. 
Phosphorylation of PKCθ at T538 was increased in Jurkat-Tat101 
cells but not in Jurkat-Tat72, which correlated with the absence 
of enhanced kinase activity in these cells. Moreover, phospho-
PKCθ was translocated to the plasma membrane in non-dividing 
Jurkat-Tat101 cells and in the absence of stimulation such as PMA 
treatment. Correlation with the intracellular expression of Tat101 
in Jurkat-Tat101 cells and the increased PKCθ activity was dem-
onstrated by treatment of Jurkat-Tat101 cells with doxycycline 
for 3 days, which completely inhibited PKCθ phosphorylation at 
T538 and its translocation to the plasma membrane, along with Tat 
functionality as was assessed by transfection with Tat-defective 
clone pNL4-3_TatM1I. Enhanced PKCθ activity in Jurkat-Tat101 
appeared to be restricted to this kinase as the activity of the closely 
related novel PKCδ was not modified.
activation of ras/raf/MeK/erK/elk-1 and 
nF-κB Pathways in Jurkat-Tat101 cells 
Was Dependent on enhanced PKcθ 
activity
We evaluated whether Ras/Raf/MEK/ERK/Elk-1 and NF-κB 
transduction pathways initiated by PKCθ were also activated 
in Jurkat-Tat101 in the absence of activating stimuli. Jurkat-
Tat101 cells showed the main component of NF-κB in CD4+ 
T cells p65/RelA was bound to -κB consensus sequences. This 
binding was interfered by transfection of siRNA directed against 
mRNA for PKCθ, proving the link between Tat and PKCθ for 
the activation of NF-κB. Moreover, Jurkat-Tat101 showed high 
LTR-dependent transcription that was also abrogated by RNA 
FigUre 7 | nuclear coexistence of PKcθ and Tat in Jurkat cells and 
human PBls. Nuclear proteins from Jurkat E6-1 cells transiently transfected 
with pCMV-Tat101 for 48 h or from PBLs infected with NL4-3_wt for 3 days 
were analyzed by sequential ChIP assay to detect the interaction between 
PKCθ and Tat in the HIV-1 LTR promoter, specifically in the region from −39 
to +66 that contains the TAR loop (+1 to +59). ChIP enrichment ratio of two 
independent experiments is represented. Data are represented as 
mean ± SEM. * and ** for p < 0.05 and p < 0.01, respectively. Schematic 
representation of the proximal HIV-1 LTR promoter show the three binding 
sites for Sp1 and the two binding sites for NF-κB, located upstream TAR 
loop.
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interference of PKCθ, proving the essential synergy between 
PKCθ-stimulated NF-κB and Tat to initiate LTR-dependent 
transcription. Similarly, Ras activity was enhanced in Jurkat-
Tat101 cells in basal conditions. Consequently, Raf/MEK/
ERK pathway was also activated, as was demonstrated by the 
detection of activating phosphorylated forms of each protein. 
Analysis of the activity of transcription factor Elk-1, located at 
the end of Ras/Raf/MEK/ERK pathway, confirmed the increased 
activation of this via in Jurkat-Tat101 cells. Phosphorylation of 
essential proteins in this pathway was especially significant in 
the case of ERK1/2 at T202/Y204, which was greatly increased in 
Jurkat-Tat101 after stimulation with PMA. RNA interference 
of PKCθ also inhibited the greatest ERK1/2 phosphorylation 
in Jurkat-Tat101, proving that Tat-mediated increased PKCθ 
activity was responsible for this event.
PKcθ and Tat101 coexisted and interacted 
in the nucleus of Jurkat cells, specifically 
in the region of the lTr Promoter that 
contains Tar loop
Once that a relationship between intracellular Tat expression 
and increased PKCθ activity was demonstrated, we tried to 
determine whether both proteins could coexist and interact in 
the nucleus of CD4+ T cells. It was observed by fluorescence 
microscopy that transient overexpression of Tat101 in Jurkat 
cells greatly increased PKCθ phosphorylation at T538 in the 
nucleus. Nuclear colocalization of both proteins was deter-
mined in an optical section through the middle of the cell – z 
axis – by confocal microscopy. Calculation of intensity mean 
values per each channel determined the presence of colocaliza-
tion spots inside the nucleus. The possible interaction between 
Tat and PKCθ was confirmed by sequential ChIP in nuclear 
protein extracts from Jurkat cells transfected with the HIV-1 
infectious clone pNL4-3_wt and from PBLs infected with 
NL4-3_wt for 3 days. ChIP results showed that Tat and PKCθ 
were interacting at the downstream region of the HIV-1 LTR 
promoter, specifically in the region that contains TAR loop, 
where Tat binds to ensure an efficient elongation of the viral 
transcripts. Intriguingly, transient overexpression of Tat101 or 
in  vitro acute HIV-1 infection induced a high level of phos-
phorylation of PKCθ at T538 and its preferential translocation 
to the nucleus of the infected cell. However, stable expression 
of Tat101 in an established cell line caused translocation of 
phospho-PKCθ mostly to the plasma membrane, where PKCθ 
would activate several transduction pathways but not directly 
interact with Tat in the nucleus, contributing indirectly to 
HIV-1 replication through the activation of essential factors 
such as ERK and NF-κB. Both mechanisms could be related 
to the different viral replication level observed in vivo during 
acute and chronic infection.
In conclusion, in this study, we described the effect of stable 
expression of intracellular Tat101 and Tat72 on the activity of 
the essential kinase PKCθ in CD4+ T cells. Intracellular Tat101 
was more potent at enhancing PKCθ activity that Tat72, proving 
that although Tat72 may be sufficient for the elongation of viral 
transcripts, the presence of the second exon in Tat101 greatly 
increased its positive effect on PKCθ kinase activity. Tat101 was 
able to induce PKCθ phosphorylation at T538 and its transloca-
tion to the plasma membrane or to the nucleus, in the absence of 
activating stimuli, promoting the activation of signal transduc-
tion pathways such as Ras/Raf/MEK/ERK and NF-κB, essential 
for HIV-1 full replication. Due to the importance of PKCθ for 
T-cell activation, more analysis will be needed to confirm the role 
of nuclear PKCθ to directly enhance viral transcription during 
HIV-1 infection and not only indirectly through the activation of 
transcription factors such as NF-κB and Elk-1. Nuclear coexist-
ence between PKCθ and Tat during acute HIV-1 infection could 
be used as a therapeutic target because selective PKCθ inhibi-
tors could disrupt this association and avoid the massive HIV-1 
replication and CD4 depletion that occur during the first stages 
of the illness.
aUThOr cOnTriBUTiOns
MC and JA conceived the study and interpreted the results. ML-H 
performed the immunofluorescence assays and most immuno-
blotting assays. SR-M and EM performed transfections, kinase 
activity, flow cytometry, and qPCR assays. CG-D performed the 
study about Ras/Raf/MEK/ERK/Elk-1 pathway. JL, AZ, and SR 
performed the ChIP assays. All authors revised critically the 
contents of the article.
acKnOWleDgMenTs
We greatly appreciate the secretarial assistance of Mrs. Olga 
Palao. We also thank Centro Regional de Transfusión Castilla-La 
Mancha (Toledo, Spain), for providing the buffy coats.
FUnDing
This work was supported by the Spanish Ministry of Economy 
and Competitiveness (SAF2010-18388, SAF2013-44677-R, FIS 
PI12/00506); FIPSE (360924/10); the SPANISH AIDS Research 
Network RD12/0017/0015 that is included in the Spanish 
I + D + I Plan and is cofinanced by ISCIII-Subdirección General 
de Evaluacion and European Funding for Regional Development 
(FEDER); EUROPRISE Network of Excellence of the EU, grant 
number LSHP CT-2006-037611, and Agence nationale de 
recherches sur le sida et les hépatites virales (ANRS 2014-2). The 
work of EM is supported by a contract of the Instituto de Salud 
Carlos III (Spain) (MPY 1371/12). The work of SR-M is sup-
ported by a fellowship of Sara Borrell from Spanish Ministry of 
Economy and Competitiveness. The work of ML-H is supported 
by a fellowship of the European Union Programme Health 2009 
(CHAARM).
February 2016 | Volume 7 | Article 6913
López-Huertas et al. Interaction between PKC-Theta and HIV-1 Tat
Frontiers in Immunology | www.frontiersin.org
reFerences
1. Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, et al. High levels 
of HIV-1 in plasma during all stages of infection determined by competitive 
PCR. Science (1993) 259(5102):1749–54. doi:10.1126/science.8096089 
2. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al. 
CD4+ T cell depletion during all stages of HIV disease occurs predominantly 
in the gastrointestinal tract. J Exp Med (2004) 200(6):749–59. doi:10.1084/
jem.20040874 
3. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, et al. 
Primary HIV-1 infection is associated with preferential depletion of CD4+ T 
lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 
200(6):761–70. doi:10.1084/jem.20041196 
4. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establish-
ment of a pool of latently infected, resting CD4(+) T cells during primary 
HIV-1 infection. Proc Natl Acad Sci U S A (1998) 95(15):8869–73. doi:10.1073/
pnas.95.15.8869 
5. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, 
et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 
(2006) 194(1):11–9. doi:10.1086/505147 
6. Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, et al. 
Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. 
Nature (2014) 512(7512):74–7. doi:10.1038/nature13594 
7. Gougeon ML. To kill or be killed: how HIV exhausts the immune system. Cell 
Death Differ (2005) 12(Suppl 1):845–54. doi:10.1038/sj.cdd.4401616 
8. Varbanov M, Espert L, Biard-Piechaczyk M. Mechanisms of CD4 T-cell 
depletion triggered by HIV-1 viral proteins. AIDS Rev (2006) 8(4):221–36. 
9. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. Understanding 
HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat 
Rev Microbiol (2009) 7(11):798–812. doi:10.1038/nrmicro2223 
10. Meller N, Altman A, Isakov N. New perspectives on PKCtheta, a member 
of the novel subfamily of protein kinase C. Stem Cells (1998) 16(3):178–92. 
doi:10.1002/stem.160178 
11. Baier G, Telford D, Giampa L, Coggeshall KM, Baier-Bitterlich G, Isakov N, 
et al. Molecular cloning and characterization of PKC theta, a novel member of 
the protein kinase C (PKC) gene family expressed predominantly in hemato-
poietic cells. J Biol Chem (1993) 268(7):4997–5004. 
12. Isakov N, Altman A. Protein kinase C(theta) in T cell activation. Annu Rev 
Immunol (2002) 20:761–94. doi:10.1146/annurev.immunol.20.100301.064807 
13. Baier G. The PKC gene module: molecular biosystematics to resolve its T cell func-
tions. Immunol Rev (2003) 192:64–79. doi:10.1034/j.1600-065X.2003.00018.x 
14. Wang X, Chuang HC, Li JP, Tan TH. Regulation of PKC-theta function by 
phosphorylation in T cell receptor signaling. Front Immunol (2012) 3:197. 
doi:10.3389/fimmu.2012.00197 
15. Liu Y, Graham C, Li A, Fisher RJ, Shaw S. Phosphorylation of the protein kinase 
C-theta activation loop and hydrophobic motif regulates its kinase activity, but 
only activation loop phosphorylation is critical to in vivo nuclear-factor-kap-
paB induction. Biochem J (2002) 361(Pt 2):255–65. doi:10.1042/bj3610255 
16. Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, et al. The 
immunological synapse: a molecular machine controlling T cell activation. 
Science (1999) 285(5425):221–7. doi:10.1126/science.285.5425.221 
17. Coudronniere N, Villalba M, Englund N, Altman A. NF-kappa B activation 
induced by T cell receptor/CD28 costimulation is mediated by protein 
kinase C-theta. Proc Natl Acad Sci U S A (2000) 97(7):3394–9. doi:10.1073/
pnas.97.7.3394 
18. Dustin ML, Chan AC. Signaling takes shape in the immune system. Cell (2000) 
103(2):283–94. doi:10.1016/S0092-8674(00)00120-3 
19. Alcami J, Lain de LT, Folgueira L, Pedraza MA, Jacque JM, Bachelerie F, et al. 
Absolute dependence on kappa B responsive elements for initiation and Tat-
mediated amplification of HIV transcription in blood CD4 T lymphocytes. 
EMBO J (1995) 14(7):1552–60. 
20. Lopez-Huertas MR, Mateos E, Diaz-Gil G, Gomez-Esquer F, Sanchez Del 
CM, Alcami J, et al. Protein kinase Ctheta is a specific target for inhibition 
of the HIV type 1 replication in CD4+ T lymphocytes. J Biol Chem (2011) 
286(31):27363–77. doi:10.1074/jbc.M110.210443 
21. Bermejo M, Lopez-Huertas MR, Hedgpeth J, Mateos E, Rodriguez-Mora 
S, Maleno MJ, et  al. Analysis of protein kinase C theta inhibitors for the 
control of HIV-1 replication in human CD4+ T cells reveals an effect on 
retrotranscription in addition to viral transcription. Biochem Pharmacol 
(2015) 94(4):241–56. doi:10.1016/j.bcp.2015.02.009 
22. Sutcliffe EL, Bunting KL, He YQ, Li J, Phetsouphanh C, Seddiki N, et  al. 
Chromatin-associated protein kinase C-theta regulates an inducible gene 
expression program and microRNAs in human T lymphocytes. Mol Cell 
(2011) 41(6):704–19. doi:10.1016/j.molcel.2011.02.030 
23. Gaynor RB. Regulation of HIV-1 gene expression by the transactivator protein 
Tat. Curr Top Microbiol Immunol (1995) 193:51–77. 
24. Rana TM, Jeang KT. Biochemical and functional interactions between HIV-1 
Tat protein and TAR RNA. Arch Biochem Biophys (1999) 365(2):175–85. 
doi:10.1006/abbi.1999.1206 
25. Berkhout B, Jeang KT. Trans activation of human immunodeficiency virus 
type 1 is sequence specific for both the single-stranded bulge and loop of 
the trans-acting-responsive hairpin: a quantitative analysis. J Virol (1989) 
63(12):5501–4. 
26. Marcello A, Zoppe M, Giacca M. Multiple modes of transcriptional regu-
lation by the HIV-1 Tat transactivator. IUBMB Life (2001) 51(3):175–81. 
doi:10.1080/152165401753544241 
27. Zhou M, Halanski MA, Radonovich MF, Kashanchi F, Peng J, Price DH, 
et al. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA 
polymerase II carboxyl-terminal domain during human immunodeficiency 
virus type 1 transcription. Mol Cell Biol (2000) 20(14):5077–86. doi:10.1128/
MCB.20.14.5077-5086.2000 
28. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, 
et al. Release, uptake, and effects of extracellular human immunodeficiency 
virus type 1 Tat protein on cell growth and viral transactivation. J Virol (1993) 
67(1):277–87. 
29. Jeang KT, Xiao H, Rich EA. Multifaceted activities of the HIV-1 transactivator 
of transcription, Tat. J Biol Chem (1999) 274(41):28837–40. doi:10.1074/
jbc.274.41.28837 
30. Carroll R, Martarano L, Derse D. Identification of lentivirus tat functional 
domains through generation of equine infectious anemia virus/human 
immunodeficiency virus type 1 tat gene chimeras. J Virol (1991) 65(7):3460–7. 
31. Demarchi F, Gutierrez MI, Giacca M. Human immunodeficiency virus type 
1 tat protein activates transcription factor NF-kappaB through the cellular 
interferon-inducible, double-stranded RNA-dependent protein kinase, PKR. 
J Virol (1999) 73(8):7080–6. 
32. Lopez-Huertas MR, Callejas S, Abia D, Mateos E, Dopazo A, Alcami J, et al. 
Modifications in host cell cytoskeleton structure and function mediated by 
intracellular HIV-1 Tat protein are greatly dependent on the second coding 
exon. Nucleic Acids Res (2010) 38(10):3287–307. doi:10.1093/nar/gkq037 
33. Blanco A, Alvarez S, Fresno M, Munoz-Fernandez MA. Extracellular HIV-Tat 
induces cyclooxygenase-2 in glial cells through activation of nuclear factor of acti-
vated T cells. J Immunol (2008) 180(1):530–40. doi:10.4049/jimmunol.180.1.530 
34. Mischiati C, Pironi F, Milani D, Giacca M, Mirandola P, Capitani S, 
et  al. Extracellular HIV-1 Tat protein differentially activates the JNK and 
ERK/MAPK pathways in CD4 T cells. AIDS (1999) 13(13):1637–45. 
doi:10.1097/00002030-199909100-00006 
35. Weiss A, Wiskocil RL, Stobo JD. The role of T3 surface molecules in the activa-
tion of human T cells: a two-stimulus requirement for IL 2 production reflects 
events occurring at a pre-translational level. J Immunol (1984) 133(1):123–8. 
36. Arenzana-Seisdedos F, Fernandez B, Dominguez I, Jacque JM, Thomas D, 
Diaz-Meco MT, et al. Phosphatidylcholine hydrolysis activates NF-kappa B 
and increases human immunodeficiency virus replication in human mono-
cytes and T lymphocytes. J Virol (1993) 67(11):6596–604. 
37. Bachelerie F, Alcami J, Arenzana-Seisdedos F, Virelizier JL. HIV enhancer 
activity perpetuated by NF-kappa B induction on infection of monocytes. 
Nature (1991) 350(6320):709–12. doi:10.1038/350709a0 
38. Zarich N, Oliva JL, Martinez N, Jorge R, Ballester A, Gutierrez-Eisman S, et al. 
Grb2 is a negative modulator of the intrinsic Ras-GEF activity of hSos1. Mol 
Biol Cell (2006) 17(8):3591–7. doi:10.1091/mbc.E05-12-1104 
39. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, et  al. 
Production of acquired immunodeficiency syndrome-associated retrovirus in 
human and nonhuman cells transfected with an infectious molecular clone. 
J Virol (1986) 59(2):284–91. 
40. Lopez-Huertas MR, Mateos E, Sanchez Del CM, Gomez-Esquer F, Diaz-Gil 
G, Rodriguez-Mora S, et al. The presence of HIV-1 Tat protein second exon 
delays fas protein-mediated apoptosis in CD4+ T lymphocytes: a potential 
February 2016 | Volume 7 | Article 6914
López-Huertas et al. Interaction between PKC-Theta and HIV-1 Tat
Frontiers in Immunology | www.frontiersin.org
mechanism for persistent viral production. J Biol Chem (2013) 288(11):7626–
44. doi:10.1074/jbc.M112.408294 
41. Zhang D, Anantharam V, Kanthasamy A, Kanthasamy AG. Neuroprotective 
effect of protein kinase C delta inhibitor rottlerin in cell culture and animal 
models of Parkinson’s disease. J Pharmacol Exp Ther (2007) 322(3):913–22. 
doi:10.1124/jpet.107.124669 
42. Bradford MM. A rapid and sensitive method for the quantitation of micro-
gram quantities of protein utilizing the principle of protein-dye binding. Anal 
Biochem (1976) 72:248–54. doi:10.1016/0003-2697(76)90527-3 
43. Lain de LT, Folgueira L, Martin AG, Dargemont C, Pedraza MA, Bermejo M, 
et al. Expression of IkappaBalpha in the nucleus of human peripheral blood 
T lymphocytes. Oncogene (1999) 18(8):1581–8. doi:10.1038/sj.onc.1202455 
44. Meller N, Elitzur Y, Isakov N. Protein kinase C-theta (PKCtheta) distribution 
analysis in hematopoietic cells: proliferating T cells exhibit high proportions 
of PKCtheta in the particulate fraction. Cell Immunol (1999) 193(2):185–93. 
doi:10.1006/cimm.1999.1478 
45. Liu Y, Asch H, Kulesz-Martin MF. Functional quantification of DNA-binding 
proteins p53 and estrogen receptor in cells and tumor tissues by DNA affinity 
immunoblotting. Cancer Res (2001) 61(14):5402–6. 
46. Klein-Hitpass L, Schorpp M, Wagner U, Ryffel GU. An estrogen-responsive 
element derived from the 5’-flanking region of the Xenopus vitellogenin 
A2 gene functions in transfected human cells. Cell (1986) 46(7):1053–61. 
doi:10.1016/0092-8674(86)90705-1 
47. Taylor SJ, Shalloway D. Cell cycle-dependent activation of Ras. Curr Biol 
(1996) 6(12):1621–7. doi:10.1016/S0960-9822(02)70785-9 
48. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev 
Immunol (2002) 2(10):725–34. doi:10.1038/nri968 
49. Furler RL, Uittenbogaart CH. Signaling through the P38 and ERK pathways: 
a common link between HIV replication and the immune response. Immunol 
Res (2010) 48(1–3):99–109. doi:10.1007/s12026-010-8170-1 
50. Yang X, Gabuzda D. Regulation of human immunodeficiency virus type 1 
infectivity by the ERK mitogen-activated protein kinase signaling pathway. 
J Virol (1999) 73(4):3460–6. 
51. Manninen A, Renkema GH, Saksela K. Synergistic activation of NFAT by 
HIV-1 nef and the Ras/MAPK pathway. J Biol Chem (2000) 275(22):16513–7. 
doi:10.1074/jbc.M910032199 
52. Zahler AM, Damgaard CK, Kjems J, Caputi M. SC35 and heterogeneous 
nuclear ribonucleoprotein A/B proteins bind to a juxtaposed exonic splicing 
enhancer/exonic splicing silencer element to regulate HIV-1 tat exon 2 
splicing. J Biol Chem (2004) 279(11):10077–84. doi:10.1074/jbc.M312743200 
53. McCloskey TW, Ott M, Tribble E, Khan SA, Teichberg S, Paul MO, et al. Dual role 
of HIV Tat in regulation of apoptosis in T cells. J Immunol (1997) 158(2):1014–9. 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 López-Huertas, Li, Zafar, Rodríguez-Mora, García-Domínguez, 
Mateos, Alcamí, Rao and Coiras. This is an open-access article distributed under the 
terms of the Creative Commons Attribution License (CC BY). The use, distribution or 
reproduction in other forums is permitted, provided the original author(s) or licensor 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
